DataSheet_1_Improving Quality Indicator of Melanoma Management – Change of Melanoma Mortality-to-Incidence Rate Ratio Based on a Hungarian Nationwide Retrospective Study.docx

IntroductionThe incidence of melanoma has been increasing in the last decades. A retrospective Hungarian epidemiological study provided real-world data on incidence and mortality rates. There have been changing trends in incidence in Hungary in the last decade and mortality decreased, shifting mortality-to-incidence rate ratios (MIR). MIR is an indicator of cancer management quality.
ObjectivesOur aim is to show the changes of melanoma MIR in Hungary between 2011 and 2018 and to compare the real-world evidence-based results of our Hungarian nationwide retrospective study with other European countries.
MethodsMIR is calculated from the age-specific standardized incidence and mortality rates from our study. Annual MIR values are presented for the total population and for both sexes between 2011 and 2018, along with 95% confidence intervals. Comparison with European countries are shown for 2012 and 2018 based on the GLOBOCAN database and Eurostat health care expenditure per capita data.
ResultsMIR decreased by 0.035 during the study years. The decrease was same in both sexes (0.031). Male had higher MIRs in all study years. In both 2012 and 2018, Hungarian MIR in both sexes was lower than the European Union average (males: 0.192 vs. 0.212 and 0.148 vs. 0.174 respectively, women: 0.107 vs. 0.129 and 0.083 vs. 0.107 respectively).
DiscussionHungarian mortality-to-incidence ratio is the lowest in Central and Eastern Europe and is close to the level of Western and Northern European countries. The results are driven by the high number of new diagnosed melanoma cases.

【引言】近数十年来，黑色素瘤的发病率持续攀升。本项匈牙利回顾性流行病学研究提供了有关癌症发病率与死亡率的真实世界数据。过去十年间，匈牙利的黑色素瘤发病率趋势发生变化，同时死亡率有所下降，进而导致死亡率-发病率比值（mortality-to-incidence rate ratio, MIR）发生改变。MIR是衡量癌症诊疗质量的重要指标。
【研究目的】本研究旨在阐明2011至2018年间匈牙利黑色素瘤MIR的变化趋势，并将这项全国性回顾性研究基于真实世界证据获得的结果与其他欧洲国家进行对比。
【研究方法】本研究通过年龄标化发病率与死亡率计算MIR。本文展示了2011至2018年全人群及男、女性群体的年度MIR值，并附带95%置信区间。基于GLOBOCAN数据库与欧盟统计局（Eurostat）的人均医疗保健支出数据，本文对比了2012年与2018年匈牙利与欧洲各国的MIR水平。
【研究结果】研究周期内，MIR整体下降0.035。男、女性群体的MIR下降幅度一致，均为0.031。所有研究年份中，男性的MIR均高于女性。2012年与2018年，匈牙利男、女性的MIR均低于欧盟平均水平（男性分别为0.192 vs 0.212、0.148 vs 0.174；女性分别为0.107 vs 0.129、0.083 vs 0.107）。
【讨论】匈牙利的黑色素瘤死亡率-发病率比值在中东欧地区位列最低，且接近西欧与北欧国家的平均水准。本研究结果主要源于该国新增黑色素瘤确诊病例数量较多。